

Patent Cap in Drug Pricing Bill Seen as Having Muted Effect

MEDIA MENTIONS | LESS THAN 1 MIN READ

July 25, 2024


By: Ryan Davis

Law360

Axinn partner [Ted Mathias](#) was quoted in the *Law360* article, "Patent Cap in Drug Pricing Bill Seen as Having Muted Effect."

Click [here](#) to access the publication, a subscription is required.

Related People



Ted Mathias

Related Services

To subscribe to our publications, [click here](#).

Featured Insights

- Stakeholders 24th Annual CYOC Career Development Conference
SPONSORSHIP
- CompLaw 33rd Annual Advanced EU Brussels Conference
SPEAKING ENGAGEMENT
- ALM General Counsel Conference East 2024
SPEAKING ENGAGEMENT ANTITRUST
- Global Legal Group Global Class Actions Symposium 2024
SPEAKING ENGAGEMENT LITIGATION & TRIALS
- NAPABA Convention 2024
SPONSORSHIP
- Kisaco Research Pharma and Biotech Patent Litigation 2024
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- AIJA IP/TMT Seminar // 11th Antitrust Annual Conference
SPEAKING ENGAGEMENT ANTITRUST
- EDTX Bench Bar Conference 2024
SPONSORSHIP ANTITRUST
- Informa Connect Antitrust Texas Conference 2024
SPEAKING ENGAGEMENT ANTITRUST
- LSPN North America Fall Conference 2024
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY

© 2024 Axinn, Veltrop & Harkrider LLP. All Rights Reserved